Selinexor, a FDA-approved XPO1 inhibitor, has shown antitumor activity in the clinic and is currently being used to treat various human tumors, including melanoma, colon cancer, glioblastoma, and small cell lung cancer40–43. The gene discussed is XPO1; the disease is malignant colon neoplasm.